You just read:

First Patient Enrolled in Mallinckrodt's Phase 2a Study of Investigational Drug MNK-6106 in Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)

News provided by

Mallinckrodt Pharmaceuticals

Aug 12, 2019, 06:45 ET